No Data
Are Robust Financials Driving The Recent Rally In HARBIN GLORIA PHARMACEUTICALS Co., LTD's (SZSE:002437) Stock?
Yuheng Pharmaceutical: 2024 Annual Report
Yuheng Pharmaceutical: Report for the first quarter of 2025
Yuheng Pharmaceutical: 2024 Annual Report Summary
Harbin Gloria Pharmaceuticals (002437.SZ) released its first-quarter performance, with a net income of 60.2523 million yuan, a year-on-year increase of 15.24%.
Harbin Gloria Pharmaceuticals (002437.SZ) released the first quarter report for 2025, in the first quarter, the company achieved revenue...
Harbin Gloria Pharmaceuticals (002437.SZ): No pharmaceuticals exported to the USA, the additional tariffs imposed by the USA have little overall impact on the company.
On April 10, Gelonghui reported that Harbin Gloria Pharmaceuticals (002437.SZ) stated on the interactive platform that the revenue achieved from overseas accounts for a relatively low proportion of the overall revenue (0.15% in the first half of 2024), and no Pharmaceutical exports to the USA, so the additional tariffs imposed by the USA have little overall impact on the company.
The Market Doesn't Like What It Sees From HARBIN GLORIA PHARMACEUTICALS Co., LTD's (SZSE:002437) Revenues Yet As Shares Tumble 27%
